国际口腔医学杂志

国际口腔医学杂志 ›› 2023, Vol. 50 ›› Issue (2): 230-236.doi: 10.7518/gjkq.2023003

• 综述 • 上一篇    下一篇

盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用

李潭(),梁新华()   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心四川大学华西口腔医院口腔外科门诊 成都 610041
  • 收稿日期:2022-07-19 修回日期:2022-11-10 出版日期:2023-03-01 发布日期:2023-03-14
  • 通讯作者: 梁新华
  • 作者简介:李潭，医师，硕士，Email：18843113788@163.com
  • 基金资助:
    国家自然科学基金(82073000)

Role of discoidin domain receptor 1 in the regulation of malignant tumor progression and therapy

Li Tan(),Liang Xin-hua.()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2022-07-19 Revised:2022-11-10 Online:2023-03-01 Published:2023-03-14
  • Contact: Xin-hua. Liang
  • Supported by:
    National Natural Science Foundation of China(82073000)

RichHTML

22

PDF (PC)

218

摘要：

盘状蛋白结构域受体1（DDR1）是特殊类型的跨膜受体酪氨酸激酶，在口腔鳞状细胞癌等多种肿瘤中异常表达，并能调控肿瘤进展相关的分子通路。DDR1可参与多种生物学过程，如细胞增殖、分化、迁移、侵袭、休眠和凋亡，还与肿瘤的上皮间充质转化、免疫排斥、代谢重编程和化疗药物耐药密切相关。部分DDR1抑制剂已在临床研究中显示出抗癌功效。本文回顾了DDR1在肿瘤进展中和DDR1抑制剂在肿瘤治疗中的作用，以期为恶性肿瘤的靶向治疗提供新思路。

关键词: 盘状蛋白结构域受体1, 口腔鳞状细胞癌, 恶性肿瘤, 抑制剂, 靶向治疗

Abstract:

Discoidin domain receptor 1 (DDR1) is a special type of transmembrane receptor tyrosine kinase that is aberrantly expressed in various tumors, including oral squamous cell carcinoma, and can regulate molecular pathways related to tumor progression. DDR1 is involved in a variety of biological processes, such as cell proliferation, differentiation, migration, invasion, dormancy, and apoptosis, and is also closely related to tumor epithelial-mesenchymal transition, immune rejection, metabolic reprogramming, and chemotherapeutic drug resistance. Some DDR1 inhibitors have shown anticancer efficacy in clinical studies. This article reviews the roles of DDR1 in tumor progression and DDR1 inhibitors in tumor therapy to provide new ideas for the targeted therapy of malignant tumors.

Key words: discoidin domain receptor 1, oral squamous cell carcinoma, malignant tumor, inhibitor, targeted therapy

中图分类号: 

  • Q 257

图 1

DDR1的结构和亚型DDR1的结构和子类型。DDR1a、b和c是激酶活性的，而DDR1d和e是激酶域缺陷的。AA：amino acid，氨基酸；DS：discoidin domain，盘状结构域；DS-like：discoidin-like domain，盘状蛋白样结构域；EJXM：extracellular juxtamembrane region，细胞外近膜区；IJXM：intracellular juxtamembrane region，细胞内近膜区；KD：kinase domain，激酶结构域；TM：transmembrane segment，跨膜片段；C-tail：尾部。"

1 Dang N, Hu J, Liu X, et al. CD167 Acts as a novel costimulatory receptor in T-cell activation[J]. J Immunother, 2009, 32(8): 773-784.
2 Iwai LK, Luczynski MT, Huang PH. Discoidin domain receptors: a proteomic portrait[J]. Cell Mol Life Sci, 2014, 71(17): 3269-3279.
3 Orgel Joseph PRO, Madhurapantula RS. A structu-ral prospective for collagen receptors such as DDR and their binding of the collagen fibril[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118478.
4 Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-me-diated apoptosis and influence p53 regulation through a positive feedback loop[J]. EMBO J, 2003, 22(6): 1289-1301.
5 Chang J, Chaudhuri O. Beyond proteases: basement membrane mechanics and cancer invasion[J]. J Cell Biol, 2019, 218(8): 2456-2469.
6 Valencia K, Ormazábal C, Zandueta C, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis[J]. Clin Cancer Res, 2012, 18(4): 969-980.
7 Hidalgo-Carcedo C, Hooper S, Chaudhry SI, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6[J]. Nat Cell Biol, 2011, 13(1): 49-58.
8 Toy KA, Valiathan RR, Núñez F, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2015, 150(1): 9-18.
9 Xu M, Cui C. Discoidin domain receptor tyrosine kinase 1 (DDR1): a novel predictor for recurrence of hepatocellular carcinoma after curative resection[J]. Med Sci Monit, 2021, 27: e933109.
10 Wu L, Zhao X, Ma H, et al. Discoidin domain receptor 1, a potential biomarker and therapeutic target in hepatocellular carcinoma[J]. Int J Gen Med, 2022, 15: 2037-2044.
11 Bonfil RD, Chen W, Vranic S, et al. Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness[J]. Cancer Cell Int, 2021, 21(1): 507.
12 Sugimoto K, Ito T, Woo J, et al. Prognostic impact of phosphorylated discoidin domain receptor-1 in esophageal cancer[J]. J Surg Res, 2019, 235: 479-486.
13 Chou ST, Peng HY, Mo KC, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1[J]. J Exp Clin Cancer Res, 2019, 38(1): 281.
14 Chen YL, Tsai WH, Ko YC, et al. Discoidin domain receptor-1 (DDR1) is involved in angiolymphatic invasion in oral cancer[J]. Cancers (Basel), 2020, 12(4): E841.
15 Zhu X, Yao M, Zhang B, et al. Biological information and functional analysis reveal the role of discoidin domain receptor 1 in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(2): 221-230.
16 Lai SL, Tan ML, Hollows RJ, et al. Collagen indu-ces a more proliferative, migratory and chemoresistant phenotype in head and neck cancer via DDR1[J]. Cancers (Basel), 2019, 11(11): E1766.
17 Takai K, Drain AP, Lawson DA, et al. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers[J]. Genes Dev, 2018, 32(3/4): 244-257.
18 Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, et al. Altered expression of DDR1 in clear cell renal cell carcinoma correlates with miR-199a/b-5p and patients’ outcome[J]. Cancer Genomics Proteomics, 2019, 16(3): 179-193.
19 Wasinski B, Sohail A, Bonfil RD, et al. Discoidin domain receptors, DDR1b and DDR2, promote tumour growth within collagen but DDR1b suppres-ses experimental lung metastasis in HT1080 xenografts[J]. Sci Rep, 2020, 10(1): 2309.
20 Zhao Z, Zhao S, Luo L, et al. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition[J]. Br J Cancer, 2021, 124(5): 982-994.
21 Xiao Q, Jiang Y, Liu Q, et al. Minor Type Ⅳ collagen α5 chain promotes cancer progression through discoidin domain receptor-1[J]. PLoS Genet, 2015, 11(5): e1005249.
22 Chappell WH, Candido S, Abrams SL, et al. In-fluences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines[J]. Aging (Albany NY), 2020, 12(11): 10194-10210.
23 Deng J, Kang Y, Cheng CC, et al. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis[J]. JCI Insight, 2021, 6(17): 146133.
24 Dai W, Liu S, Wang S, et al. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma[J]. Signal Transduct Target Ther, 2021, 6(1): 176.
25 Ziegler AN, Chidambaram S, Forbes BE, et al. Insulin-like growth factor-Ⅱ (IGF-Ⅱ) and IGF-Ⅱ analogs with enhanced insulin receptor-a binding affinity promote neural stem cell expansion[J]. J Biol Chem, 2014, 289(8): 4626-4633.
26 Vella V, Malaguarnera R. The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12): E3814.
27 Vella V, Nicolosi ML, Cantafio P, et al. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop[J]. Endocr Relat Cancer, 2019, 26(1): 197-214.
28 Di Martino JS, Nobre AR, Mondal C, et al. A tumor-derived type Ⅲ collagen-rich ECM niche regulates tumor cell dormancy[J]. Nat Cancer, 2022, 3(1): 90-107.
29 Wang CZ, Su HW, Hsu YC, et al. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration[J]. Mol Biol Cell, 2006, 17(6): 2839-2852.
30 Azizi R, Salemi Z, Fallahian F, et al. Inhibition of didscoidin domain receptor 1 reduces epithelial-me-senchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines[J]. J Cell Physiol, 2019, 234(11): 19539-19552.
31 Azizi R, Fallahian F, Aghaei M, et al. Down-regulation of DDR1 induces apoptosis and inhibits EMT through phosphorylation of Pyk2/MKK7 in DU-145 and lncap-FGC prostate cancer cell lines[J]. Anticancer Agents Med Chem, 2020, 20(8): 1009-1016.
32 Chung VY, Tan TZ, Huang RL, et al. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer[J]. Gene, 2017, 635: 9-15.
33 Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition[J]. Matrix Biol, 2011, 30(4): 243-247.
34 Le CC, Bennasroune A, Collin G, et al. LRP-1 promotes colon cancer cell proliferation in 3D collagen matrices by mediating DDR1 endocytosis[J]. Front Cell Dev Biol, 2020, 8: 412.
35 Xie X, Rui W, He W, et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer[J]. Am J Transl Res, 2017, 9(5): 2500-2507.
36 Griffith OL, Spies NC, Anurag M, et al. The prognostic effects of somatic mutations in ER-positive breast cancer[J]. Nat Commun, 2018, 9(1): 3476.
37 Ben Arfi K, Schneider C, Bennasroune A, et al. Discoidin domain receptor 1 expression in colon cancer: roles and prognosis impact[J]. Cancers (Basel), 2022, 14(4): 928.
38 Reger de Moura C, Battistella M, Sohail A, et al. Discoidin domain receptors: a promising target in melanoma[J]. Pigment Cell Melanoma Res, 2019, 32(5): 697-707.
39 Chen Y, Wang X, Deng X, et al. DNA damage repair status predicts opposite clinical prognosis immunotherapy and non-immunotherapy in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 6769-22.
40 Dimitrios L, Enrico K. Barring the gates to the battleground: DDR1 promotesimmune exclusion in so-lid tumors[J]. Signal Transduct Target Ther, 2022, 7(1): 17.
41 Sun X, Wu B, Chiang HC, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion[J]. Nature, 2021, 599(7886): 673-678.
42 Zhong X, Zhang W, Sun T. DDR1 promotes breast tumor growth by suppressing antitumor immunity[J]. Oncol Rep, 2019, 42(6): 2844-2854.
43 [No authors listed]. Collagen receptor implicated in immune exclusion[J]. Cancer Discov, 2022, 12(1): 6.
44 Vella V, Malaguarnera R, Nicolosi ML, et al. Insulin/IGF signaling and discoidin domain receptors: an emerging functional connection[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118522.
45 Vella V, Giuliano M, Nicolosi ML, et al. DDR1 affects metabolic reprogramming in breast cancer cells by cross-talking to the insulin/IGF system[J]. Biomolecules, 2021, 11(7): 926.
46 Lin Y, Jin H, Wu X, et al. The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(14): 14391-14405.
47 Denny WA, Flanagan JU. Inhibitors of discoidin domain receptor (DDR) kinases for cancer and inflammation[J]. Biomolecules, 2021, 11(11): 1671.
48 Tao Y, Wang R, Lai Q, et al. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma[J]. Mol Oncol, 2019, 13(9): 1855-1873.
49 Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib[J]. Eur J Pharmacol, 2008, 599(1/2/3): 44-53.
50 Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors[J]. Nat Biotechnol, 2019, 37(9): 1038-1040.
51 Shariati M, Evans KW, Zheng X, et al. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations[J]. Oncogene, 2021, 40(26): 4425-4439.
52 Bhanumathy KK, Balagopal A, Vizeacoumar FS, et al. Protein tyrosine kinases: their roles and their targeting in leukemia[J]. Cancers (Basel), 2021, 13(2): E184.
53 Berestjuk I, Lecacheur M, Carminati A, et al. Targe-ting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma[J]. EMBO Mol Med, 2022, 14(2): e11814.
54 Vehlow A, Cordes N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy[J]. Autophagy, 2019, 15(8): 1487-1488.
55 Vehlow A, Klapproth E, Jin S, et al. Interaction of discoidin domain receptor 1 with a 14-3-3-beclin-1-Akt1 complex modulates glioblastoma therapy sensitivity[J]. Cell Rep, 2019, 26(13): 3672-3683.e7.
[1] 周金阔,张晋弘,史晓晶,刘广顺,姜磊,刘倩峰. 长链非编码RNA小核仁RNA宿主基因22调控微小RNA-27b-3p对口腔鳞状细胞癌细胞增殖、侵袭和迁移的影响[J]. 国际口腔医学杂志, 2024, 51(1): 52-59.
[2] 李立恒,王蕊,王晓明,张智轶,张璇,安峰,王芹,张凡. 环状RNA hsa_circ_0085576调控微小RNA-498/B细胞特异性莫洛尼鼠白血病病毒整合位点1轴对口腔鳞状细胞癌细胞迁移和侵袭的影响[J]. 国际口腔医学杂志, 2024, 51(1): 60-67.
[3] 吴佳敏,夏斌,杨禾丰,许彪. 癌相关成纤维细胞在口腔鳞状细胞癌微环境中作用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 711-717.
[4] 柳江龙, 买买提吐逊·吐尔地. 超声造影在口腔鳞状细胞癌颈部转移性淋巴结诊断中的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 514-520.
[5] 赵玲帆, 周杨, 叶鑫鑫, 张强. 肾移植术后腮腺低分化黏液表皮样癌1例[J]. 国际口腔医学杂志, 2023, 50(4): 419-422.
[6] 盛南宁,王珏,南欣荣. 性别决定基因盒9在口腔鳞状细胞癌作用机制和治疗中的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 314-320.
[7] 李洪芳,陈中,张素欣. 免疫检查点抑制剂联合放射治疗在头颈部鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 614-620.
[8] 赵卓平,辛鹏飞,高阳,张彩凤,张宽收,刘青梅. 光热治疗在口腔鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 462-470.
[9] 陈思婷,钟雄,孟文霞. Nod样受体家族嘌呤结构域3炎症小体在口腔黏膜病中的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 471-475.
[10] 江涵,神应强,陈谦明. 毒蕈碱受体通过Yes相关蛋白信号对口腔鳞状细胞癌生物学行为的实验研究[J]. 国际口腔医学杂志, 2022, 49(2): 138-143.
[11] 蒋宇磊,夏斌,饶南荃,杨禾丰,许彪. 外泌体在口腔鳞状细胞癌恶性进展及诊疗应用的研究[J]. 国际口腔医学杂志, 2021, 48(6): 711-717.
[12] 钱颖,龚佳幸,俞梦飞,刘宇,魏栋,朱子羽,陆科杰,王慧明. 从分子生物学角度对成釉细胞瘤诊断及治疗的考量[J]. 国际口腔医学杂志, 2021, 48(5): 570-578.
[13] 马平川,李春洁,李龙江. 唾液腺导管癌的诊疗研究进展[J]. 国际口腔医学杂志, 2021, 48(4): 459-467.
[14] 甘建国,高攀,王晓毅. 循环肿瘤细胞与口腔鳞状细胞癌相关性的研究进展[J]. 国际口腔医学杂志, 2021, 48(2): 205-212.
[15] 黄俊文,乔洁,梅子,陈茁,李杨,乔彬. 脂多糖结合蛋白在口腔鳞状细胞癌中的表达及其临床意义[J]. 国际口腔医学杂志, 2021, 48(1): 50-57.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 王昆润. 修补颌骨缺损的新型生物学相容材料[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 陆加梅. 不可复性关节盘移位患者术前张口度与关节镜术后疗效的相关性[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 王昆润. 咀嚼口香糖对牙周组织微循环的影响[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 宋红. 青少年牙周炎外周血分叶核粒细胞的趋化功能[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 高卫民,李幸红. 发达国家牙医学院口腔种植学教学现状[J]. 国际口腔医学杂志, 1999, 26(06): .
[6] 侯锐. 正畸患者釉白斑损害的纵向激光荧光研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 轩东英. 不同赋形剂对氢氧化钙抗菌效果的影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[8] 房兵. 唇腭裂新生儿前颌骨矫正方法及对上颌骨生长发育的影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[9] 杨美祥. 前牙厚度在预测上下颌牙量协调性中的作用[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 赵艳丽. 手术刀、电凝、CO_2和KTP激光对大鼠舌部创口的作用[J]. 国际口腔医学杂志, 1999, 26(04): .